.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
McKesson
Colorcon
McKinsey
Cantor Fitzgerald
Teva
Merck
Julphar
Dow
Healthtrust

Generated: July 22, 2017

DrugPatentWatch Database Preview

Actelion Pharms Ltd Company Profile

« Back to Dashboard

What is the competitive landscape for ACTELION PHARMS LTD, and what generic alternatives to ACTELION PHARMS LTD drugs are available?

ACTELION PHARMS LTD has seven approved drugs.

There are sixteen US patents protecting ACTELION PHARMS LTD drugs.

There are one hundred and eighty-four patent family members on ACTELION PHARMS LTD drugs in thirty-six countries.

Summary for Applicant: Actelion Pharms Ltd

Patents:16
Tradenames:7
Ingredients:7
NDAs:7
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion Pharms Ltd
VALCHLOR
mechlorethamine hydrochloride
GEL;TOPICAL202317-001Aug 23, 2013RXYesYes8,501,818► SubscribeY ► Subscribe
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-006Dec 21, 2015RXYesNo7,205,302► SubscribeYY ► Subscribe
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-005Dec 21, 2015RXYesNo► Subscribe► Subscribe
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-008Dec 21, 2015RXYesYes7,205,302► SubscribeYY ► Subscribe
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-003Dec 21, 2015RXYesNo8,791,122► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Actelion Pharms Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Actelion Pharms Ltd
ZAVESCA
miglustat
CAPSULE;ORAL021348-001Jul 31, 20035,472,969► Subscribe
Actelion Pharms Ltd
TRACLEER
bosentan
TABLET;ORAL021290-001Nov 20, 20015,292,740► Subscribe
Actelion Pharms Ltd
TRACLEER
bosentan
TABLET;ORAL021290-002Nov 20, 20015,292,740► Subscribe
Actelion Pharms Ltd
ZAVESCA
miglustat
CAPSULE;ORAL021348-001Jul 31, 20035,525,616► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Actelion Pharms Ltd

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,809,334Therapeutic compositions containing macitentan► Subscribe
9,440,931Form-III crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide and use thereof► Subscribe
7,285,549Sulfamides and their use as endothelin receptor antagonists► Subscribe
9,340,516Form-II crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl) acetamide, method for producing the same, and use thereof► Subscribe
8,501,817Stabilized compositions of alkylating agents and methods of using same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Actelion Pharms Ltd Drugs

Country Document Number Estimated Expiration
Spain2393117► Subscribe
China102099026► Subscribe
New Zealand575702► Subscribe
South Korea20120109457► Subscribe
Canada2431675► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Actelion Pharms Ltd Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90017-3Sweden► SubscribePRODUCT NAME: BOSENTAN ELLER ETT SALT DAERAV; NAT. REGISTZRATION NO/DATE: EU/1/02/220/001 20020515; FIRST REGISTRATION: CH 55841 01 20020228
0836Netherlands► SubscribePRODUCT NAME: SELEXIPAG OF EEN ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1083 20160519
00672Netherlands► SubscribePRODUCT NAME: MACITENTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/893/001-003 20131220
381Luxembourg► SubscribePRODUCT NAME: MACITENTAN ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES(OPSUMIT)
2016000077Germany► SubscribePRODUCT NAME: SELEXIPAG ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1083/001-010 20160512
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Argus Health
Covington
Dow
Cantor Fitzgerald
UBS
Accenture
Julphar
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot